Actavis Recalls Over 65 Generic Drugs Made at NJ Plant
On August 1, 2008, Actavis Totowa, LLC announced the recall of over 65 different generic drugs the company manufactured at the same New Jersey plant where they previously produced defective Digitek tablets which were recalled in April 2008. The recall was extended to all medications made at the plant after an FDA investigation found that the drug maker was not following good manufacturing practices.
The Actavis recall applies to products remaining on shelves at hospitals and pharmacies, but does not specifically apply to drugs which have already been given to consumers. Patients have been advised that they should not stop taking their drugs, as sudden stoppage could cause serious problems. However, if they are concerned about the quality of the medications, they have been asked to contact their doctors to discuss the alternatives.
The list of recalled generic drugs includes a variety of prescription medications, including antidepressants, diet medications, painkillers and drugs for hypertension and blood pressure. Some of the impacted generics include Amantadine 100mg capsules, Amidrine capsules, Bellamine and Buspirone tablets, Carisoprodol tablet, Meperidine and Mirtazapine tablets, Naltrexone tablets and Oxycodone capsules, Pentazocine tablets and Rifampin capsules, among others.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Actavis Totowa, LLC is a generic drug manufacturer and a subsidiary of the Actavis Group. However, the recall only applies to medications produced by Actavis Totowa LLC at the Little Falls, New Jersey plant and does not apply to any drugs manufactured by Actavis Elizabeth LLC, Actavis South Atlantic or LLC Actavis Mid Atlantic LLC.
In April 2008, Actavis issued a recall for all lots of a generic form digoxin, known as Digitek, which was manufactured at this same New Jersey plant. The Digitek recall was issued after it was discovered that tablets were being sold that were twice as thick as they were supposed to be, containing up to double the appropriate amount of the pharmaceutical ingredient.
The double strength Digitek tablets have caused hundreds of people to suffer serious health problems associated with a digoxin overdose, and a number of Digitek lawsuits have already been filed in federal and state courts alleging that Actavis knew or should have known about the manufacturing problems and product defects, which made Digitek unreasonably dangerous and unfit for its intended purpose.
Prior to the Digitek recall, Actavis received warning letters from the FDA in February 2007 and August 2006 about poor manufacturing practices at the New Jersey plant. They have been accused of failing to provide periodic safety reports, failing to properly maintain equipment and failing to maintain standards of purity, identity, quality and strength of drugs made at the plant.
In a statement published on their website late Friday, Actavis Totowa indicated that they are implementing corrective actions at the New Jersey plant to return the products to the market at a future unspecified date.
A.R.September 19, 2018 at 9:37 pm
So is this the same problem that's going on now, resulting in my problems with getting decent quality medication?
Following Recalls, Digitek Manufacturer to Remain Shut Down : AboutLawsuits.comNovember 17, 2008 at 3:53 pm
[...] August 1, 2008, Actavis Totowa was also forced to recall over 65 different generic drugs due to non-compliance with Good Manufacturing Practice requirements at the same New Jersey plant. [...]
Congress Requests Information from FDA about Digitek Recall : AboutLawsuits.comOctober 10, 2008 at 2:49 pm
[...] August 2008, over 66 generic drugs made by Actavis Totowa at the same New Jersey plant were recalled after an FDA inspection uncovered [...]
"*" indicates required fields
More Top Stories
The U.S. JPML has consolidated all Tepezza lawsuits over hearing loss before one Northern Illinois federal judge for coordinated pretrial proceedings.
Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.
More than 775 Exactech lawsuits have been filed in federal and state courts as parties work toward a plan for bellwether early test trials.